References

Types of surveillance by cancer type:

Colorectal cancer:

history & physical exam, CEA, and CT scan⁴

Breast cancer:

history & physical exam and mammography²

Lung cancer:

history & physical exam and chest CT scan³

Integrate MRD testing into existing guideline-recommended surveillance for colorectal, breast, and lung
cancers.1-3*

Supplement current standard-of-care surveillance practices over the first 5 years.2-4*

Talk with a booth representative to discover more about MRD detection and ctDNA monitoring with Guardant Reveal for CRC.

CEA, carcinoembryonic antigen; CRC, colorectal cancer; CT, computerized tomography; ctDNA, circulating tumor DNA; MRD, minimal residual disease.

Important Note: The Guardant Reveal test was developed, and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. Guardant Reveal refers to Guardant Reveal Laboratory Developed Test (LDT). This test has not been cleared or approved by the US FDA.

*For invasive carcinomas and inflammatory breast cancers and non-small cell lung cancer (adenocarcinoma, large cell, and squamous).5,6